# A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

> **NCT03591926** · PHASE2 · WITHDRAWN · sponsor: **Biosplice Therapeutics, Inc.**

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** SM04646

## Key facts

- **NCT ID:** NCT03591926
- **Lead sponsor:** Biosplice Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 1900-01
- **Primary completion:** 1900-01
- **Final completion:** 1900-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn for business reasons prior to screening or enrolling any subjects.
- **Last updated:** 2018-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03591926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03591926, "A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03591926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*